Prince Pharmaceutical Co., Ltd. (6935) fair value: what the stock is really worth
As of Sep 24, 2026: fair value of Prince Pharmaceutical Co., Ltd. TWD 60.64, price TWD 28.50, upside +112.8%, quality 60 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Prince Pharmaceutical Co., Ltd. for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
Prince Pharmaceutical Co., Ltd. manufactures and sells vitamin B1 active pharmaceutical ingredients (APIs) in Taiwan, Japan, Korea, and internationally.
Show more
Prince Pharmaceutical Co., Ltd. manufactures and sells vitamin B1 active pharmaceutical ingredients (APIs) in Taiwan, Japan, Korea, and internationally. The company also offers health food and medicines; vitamin c tablets, vitamin b complex tablets, natto and rhodiola extract capsules, probiotic sachets, and plant extract capsules; and API products comprising felbinac, aldioxa, tulobuterol, ufenamate, bisbentiamine, thiamine disulfide, potassium guaiacolsulfonate, potassium cresolsulfonate, fusultiamine hydrochloride, and fursultiamine. Prince Pharmaceutical Co., Ltd. was founded in 1962 and is headquartered in Yúnlín, Taiwan.
Stock analysis
Prince Pharmaceutical Co., Ltd. (6935) currently trades at 28.50 TWD, while our model-based Fair Value estimate is 60.64 TWD, implying the stock looks roughly 53.0% undervalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of 117.85 TWD per share, and 21 of the 26 models we run sit above the 28.50 TWD price.
Bear case: the Asset-Based group reads lowest at 15.02 TWD, and 5 of the 26 models stay below the price. Evidence for this calculation is low.
Scenario range: 30.36 TWD (bear) to 109.67 TWD (bull), the price of 28.50 TWD sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 60/100 (solid quality), in the Healthcare sector.
Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Prince Pharmaceutical Co., Ltd. reported revenue of 1.1B TWD in FY2025 versus 441M TWD in FY2021, a compound +24.4%/yr. Reported net income was 96.3M TWD in FY2025.
Key figures
Market cap 1.1B TWD (≈ $33.5M) · P/E ratio 10.9 · P/S ratio 1.00 · EPS (TTM) 2.61 TWD · Dividend yield 1.8% · Net margin 9.1% · Return on equity 12.3% · Return on assets (EBIT) 2.1%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 42 out of 100 (medium confidence).
What moves the price
The share trades about 17% below its 52-week high and 6% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −8% fair-value upside, at 113%, 6935 screens cheaper than that median.
Fair Value models
Bear 30.36 TWDFair Value 60.64 TWDBull 109.67 TWD
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then (1.55 TWD per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.90/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+53.1%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+14.0%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+29.0%
Start year 2020 (pandemic)
Revenue growth 6 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+27.2%
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 3 years), in TWD (mathematically smoothed) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 3 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Smoothed = median of all growth paths between the years of the window (trend line on the logarithm of earnings per share): a single extreme year cannot distort the rate. The reported figure stays in the tooltip. Measured in TWD: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+20.3%
Earnings growth per share plus dividend.
Earnings per share, growth per year+18.5%
Dividend (yield on the price)1.8%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.−17% → 11%
2025 sits 162% above its own trend. The rate follows the median trend of the last 3 years, not that single year.
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+6.3%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (Taiwan: IMF forecast 1.6% a year to 2030, 1.5% from 2016 to 2025) that is about +4.7% a year for the price.
Compare Prince Pharmaceutical Co., Ltd. with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 630 stocks
Beats the industry median on 13/14 measures
Overall it ranks above its industry peers.
Valuation
Quality Score60 · Above median
Fair Value upside+113% · Top 25%
Profitability
Return on equity (TTM)12% · Above median
Return on assets5% · Above median
Net margin (TTM)9% · Above median
Operating margin (TTM)14% · Above median
Growth and dividend
Revenue growth74% · Top 25%
Dividend yield (TTM)1.8% · Above median
Balance sheet
Debt / equity0.28× · Highest 25%
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Prince Pharmaceutical Co., Ltd. (6935) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of 60.64 TWD versus a price of 28.50 TWD, about +113% upside (undervalued).
What is the fair value of 6935?
Our model-based fair value for Prince Pharmaceutical Co., Ltd. is 60.64 TWD (as of Sep 24, 2026), built from audited fundamentals. The current price: 28.50 TWD.
What is the quality score of 6935?
Prince Pharmaceutical Co., Ltd. has a Quality Score of 60/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Prince Pharmaceutical Co., Ltd. (6935)?
Our model-based price target is the fair value of 60.64 TWD (as of Sep 24, 2026) from 26 valuation models. Cautious scenario 30.36 TWD, optimistic scenario 109.67 TWD. It is a calculation from audited fundamentals, not an analyst target.
What is the Prince Pharmaceutical Co., Ltd. stock forecast for 2026?
Our models put fair value at 60.64 TWD, about +113% upside versus a price of 28.50 TWD (undervalued). Cautious scenario 30.36 TWD, optimistic scenario 109.67 TWD. The calculation is refreshed regularly with new filings.
What is the revenue of Prince Pharmaceutical Co., Ltd. (6935)?
Prince Pharmaceutical Co., Ltd. reported trailing-twelve-month revenue of about 1.1B TWD (latest available figure, as of Sep 24, 2026).
Does Prince Pharmaceutical Co., Ltd. pay a dividend?
Prince Pharmaceutical Co., Ltd. currently shows a dividend yield of about 1.75% relative to its recent price (as of Sep 24, 2026).
What growth is priced into Prince Pharmaceutical Co., Ltd. (6935)?
For today's price to be fair in a discounted-cash-flow model, Prince Pharmaceutical Co., Ltd. would have to grow free cash flow by +6.3 % per year for five years (discount rate 9.3 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +29.0 % per year. As of Sep 24, 2026.
What discount rate (WACC) does the fair value of 6935 use?
Our models discount Prince Pharmaceutical Co., Ltd. at 9.3 %: a base by market capitalisation (nano), damped by beta 0.63, country premium for Taiwan. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Prince Pharmaceutical Co., Ltd. that is +6.3 % per year a year over ten years, using the same discount rate (9.3 %) and the same formula as our fair value.
How much growth has Prince Pharmaceutical Co., Ltd. (6935) delivered so far?
Over the past 5 years revenue at Prince Pharmaceutical Co., Ltd. grew +29.0 % a year. The price currently implies +6.3 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Prince Pharmaceutical Co., Ltd. (6935) growing?
The median revenue growth in the sector is +0.0 % a year. That is the yardstick for the growth priced into Prince Pharmaceutical Co., Ltd. (+6.3 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Prince Pharmaceutical Co., Ltd. (6935)?
The free-cash-flow yield on the price is 6.68 %: that much free cash flow Prince Pharmaceutical Co., Ltd. produces per unit of market value. When it exceeds the discount rate of our models (9.3 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Prince Pharmaceutical Co., Ltd. (6935)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Prince Pharmaceutical Co., Ltd. it is 60.64 TWD per share (as of Sep 24, 2026), against a price of 28.50 TWD. It is the blended result of 26 valuation models (cash flow, earnings, asset, dividend).
Is Prince Pharmaceutical Co., Ltd. stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 6935 trades below its calculated fair value: price 28.50 TWD, fair value 60.64 TWD, a gap of about +113% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 6935?
No. The price is what the market pays today (28.50 TWD); the fair value is what the company's own numbers justify (60.64 TWD). For Prince Pharmaceutical Co., Ltd. the two are 32.14 TWD per share apart. That gap is exactly why we show both numbers side by side.
How much is Prince Pharmaceutical Co., Ltd. worth?
The market values Prince Pharmaceutical Co., Ltd. at about 1.1B TWD (market capitalisation, as of Sep 24, 2026). Per share that is 28.50 TWD; our models calculate a fair value of 60.64 TWD per share.
What do the bullish and bearish scenarios say about 6935?
Our models span a range for Prince Pharmaceutical Co., Ltd.: cautious scenario 30.36 TWD, base 60.64 TWD, optimistic 109.67 TWD per share (as of Sep 24, 2026, price 28.50 TWD). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 6935?
Prince Pharmaceutical Co., Ltd. trades at a price-to-earnings ratio of 10.9 (as of Sep 24, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 60.64 TWD is built from several models across several years. Other multiples: P/B 1.3, P/S 1.0, EV/EBITDA 7.0.
How solid is the balance sheet of Prince Pharmaceutical Co., Ltd. (6935)?
Balance-sheet figures for Prince Pharmaceutical Co., Ltd. (as of Sep 24, 2026): return on equity 12.3%, debt of 0.28 per unit of equity. They feed the Quality Score of 60/100, which measures business quality independently of the share price.
How far is 6935 from its 52-week high?
Prince Pharmaceutical Co., Ltd. trades at 28.50 TWD, about 17% below its 52-week high of 34.51 TWD and 6% above the low of 26.94 TWD (as of Sep 24, 2026). Distance from the high says nothing about value: that is what the fair value of 60.64 TWD is for.
Which stocks are comparable to Prince Pharmaceutical Co., Ltd.?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Jiangsu Hengrui Pharmaceuticals Co, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Prince Pharmaceutical Co., Ltd. stock attractive at the current price?
The data as of Sep 24, 2026: price 28.50 TWD, calculated fair value 60.64 TWD (+113%), Quality Score 60/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 6935 calculated?
We run Prince Pharmaceutical Co., Ltd. through 26 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 60.64 TWD, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0 % above its aggregate fair value. Prince Pharmaceutical Co., Ltd. currently trades 113 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Prince Pharmaceutical Co., Ltd. (6935)?
The closing price on Sep 24, 2026 was 28.50 TWD. Our model-based fair value is 60.64 TWD, about +113% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Prince Pharmaceutical Co., Ltd. right now?
The price is below even our cautious bear case (30.36 TWD). The market is more pessimistic than our downside scenario. The model range is unusually wide (30.36 TWD to 109.67 TWD). The outcome hinges heavily on assumptions, so read the point estimate with caution. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid quality (60/100) at a price below fair value, the discount is the argument here, not the business quality.
Key figures of Prince Pharmaceutical Co., Ltd.
How large is the market capitalisation of Prince Pharmaceutical Co., Ltd. (6935)?
The market capitalisation of Prince Pharmaceutical Co., Ltd. is 1.1B TWD (≈ $33.5M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Prince Pharmaceutical Co., Ltd. (6935)?
The price-to-sales ratio of Prince Pharmaceutical Co., Ltd. is 1.00 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Prince Pharmaceutical Co., Ltd. (6935)?
Earnings per share at Prince Pharmaceutical Co., Ltd. are 2.61 TWD (price ÷ EPS = P/E 10.9). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Prince Pharmaceutical Co., Ltd. (6935)?
The dividend yield of Prince Pharmaceutical Co., Ltd. is 1.8% (payout 19.2%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Prince Pharmaceutical Co., Ltd. (6935)?
The net margin of Prince Pharmaceutical Co., Ltd. is 9.1% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Prince Pharmaceutical Co., Ltd. (6935)?
The return on equity (ROE) of Prince Pharmaceutical Co., Ltd. is 12.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Prince Pharmaceutical Co., Ltd. (6935)?
On an EBIT basis the return on assets of Prince Pharmaceutical Co., Ltd. is 2.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Prince Pharmaceutical Co., Ltd. (6935)?
The operating margin of Prince Pharmaceutical Co., Ltd. is 13.9% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Prince Pharmaceutical Co., Ltd. (6935)?
Revenue at Prince Pharmaceutical Co., Ltd. is growing +73.7% versus a year earlier (3y avg +14.0%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much net debt does Prince Pharmaceutical Co., Ltd. (6935) carry?
The net debt of Prince Pharmaceutical Co., Ltd. is 145M TWD (fiscal year 2025, ≈ 2.0 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Prince Pharmaceutical Co., Ltd. in the live analysis
One click puts Prince Pharmaceutical Co., Ltd. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
